Abstract
BackgroundSome studies reported the possible induction of food allergy, caused by neo-sensitization to cross-reacting allergens, during immunotherapy with aeroallergens, while other studies ruled out such possibility.ObjectivesThe aim of this study was to evaluate the development of neo-sensitization to Pen a 1 (tropomyosin) as well as the appearance of reactions after ingestion of foods containing tropomyosin as a consequence of sublingual mite immunization.Materials and methodsSpecific IgE to Tropomyosin (rPen a 1) before and after mite sublingual immunotherapy in 134 subjects were measured. IgE-specific antibodies for mite extract and recombinant allergen Pen a 1 were evaluated using the immunoenzymatic CAP system (Phadia Diagnostics, Milan, Italy).ResultsAll patients had rPen a 1 IgE negative results before and after mite SLIT and did not show positive shrimp extract skin reactivity and serological rPen a 1 IgE conversion after treatment. More important, no patient showed systemic reactions to crustacean ingestion.ConclusionsPatients did not show neo-sensitization to tropomyosin, a component of the extract (namely mite group 10) administered. An assessment of a patient's possible pre-existing sensitisation to tropomyosin by skin test and/or specific IgE prior to start mite extract immunotherapy is recommended.Trial RegistrationThis trial is registered in EudraCT, with the ID number of 2010-02035531.
Highlights
In developed countries respiratory allergy is an important cause of chronic illness [1] and has a significant socio-economic impact [2]
An assessment of a patient's possible pre-existing sensitisation to tropomyosin by skin test and/or specific IgE prior to start mite extract immunotherapy is recommended
One hundred and thirty-four patients were enrolled for the study, received sublingual immunotherapy (SLIT) for their mite allergy and completed the 3-year course of treatment
Summary
In developed countries respiratory allergy is an important cause of chronic illness [1] and has a significant socio-economic impact [2]. As a matter of fact, commercial extracts used for SIT contain all or almost all the sensitizing molecules, including major and minor allergens, whereas patients receiving the treatment may be sensitized to only some of them. This raises the question of whether the administration of allergen extracts during immunotherapy can induce new clinically relevant sensitizations [5], that is the appearance of IgE specific for other allergenic molecules. Some studies reported the possible induction of food allergy, caused by neo-sensitization to crossreacting allergens, during immunotherapy with aeroallergens, while other studies ruled out such possibility
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
